EMAS clinical guide: Selective estrogen receptor modulators for postmenopausal osteoporosis

Maturitas ◽  
2012 ◽  
Vol 71 (2) ◽  
pp. 194-198 ◽  
Author(s):  
Santiago Palacios ◽  
Mark Brincat ◽  
C. Tamer Erel ◽  
Marco Gambacciani ◽  
Irene Lambrinoudaki ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Postmenopausal Osteoporosis ◽  
Selective Estrogen Receptor Modulators ◽  
Estrogen Receptor Modulators ◽  
Receptor Modulators

Current understanding of selective estrogen receptor modulators

2020 ◽  
Vol 68 (6) ◽  
pp. 99-106
Author(s):  
Lyudmila S. Polyanskikh ◽  
Maria A. Petrosyan ◽  
Svetlana N. Morozkina ◽  
Elena V. Baziyan
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Postmenopausal Osteoporosis ◽  
Vertebral Fractures ◽  
Uterine Cancer ◽  
Metastatic Breast ◽  
Selective Estrogen Receptor Modulators ◽  
Estrogen Receptor Modulators ◽  
Prevention And Treatment ◽  
Receptor Modulators

Despite the variety of selective estrogen receptor modulators of different classes of compounds and their active use for the treatment of hormone-dependent breast cancer, climacteric conditions, and polycystic ovary syndrome, as well as for ovulation stimulation and for prevention and treatment of postmenopausal osteoporosis and vertebral fractures, there are a number of serious side effects, such as thromboembolic disorders, uterine cancer and endometrial cancer. Among the selective estrogen receptor modulators used in clinical practice, it is worth noting: Raloxifene, for the prevention and treatment of postmenopausal osteoporosis and vertebral fractures; Tamoxifen, for the treatment of breast cancer; Toremifene, for the treatment of metastatic breast cancer in postmenopausal women; Lasofoxifene, for the treatment of osteoporosis; Bazedoxifene, for the treatment and prevention of postmenopausal osteoporosis; Clomiphene, for the treatment of anovulatory infertility; Ospemifene, for the treatment of moderate to severe dyspareunia associated with postmenopausal syndrome. An ongoing search for an effective and safe selective estrogen receptor modulator for the treatment of endometriosis is currently underway.

Selective Estrogen Receptor Modulators for Postmenopausal Osteoporosis

Drugs & Aging ◽  
2007 ◽  
Vol 24 (5) ◽  
pp. 361-379 ◽  
Author(s):  
Luigi Gennari ◽  
Daniela Merlotti ◽  
Fabrizio Valleggi ◽  
Giuseppe Martini ◽  
Ranuccio Nuti
Keyword(s):  
Estrogen Receptor ◽  
Postmenopausal Osteoporosis ◽  
Selective Estrogen Receptor Modulators ◽  
Estrogen Receptor Modulators ◽  
Receptor Modulators
Sign in / Sign up

Export Citation Format

Share Document